Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. A definition of COPD
3. Pathology of COPD
4. Air trapping in COPD
5. Amplification of inflammation in COPD
6. Cellular mechanisms of COPD
7. NF-kappaB in COPD
8. Elastase activity of macrophages in COPD
9. Effects of MMP-9
10. Macrophages in COPD
11. GRO-alpha (CXCL1) in COPD
12. Alveolar macrophages in COPD
13. Macrophage phagocytosis in COPD (1)
14. Macrophage phagocytosis in COPD (2)
15. Macrophage phagocytosis: model
16. Microtubular function
17. CD8 cells in COPD
18. CXCR3 chemokines
19. Evolution of inflammation in COPD
20. Th17 cells
21. Th17 cells in COPD
22. Cytokines in induced sputum in COPD
23. Reduced effect of corticosteroids in COPD
24. Amplification and steroid resistance
25. HDAC2 in COPD lung
26. HDAC2 and steroid responsiveness in COPD
27. Corticosteroid resistance in COPD (1)
28. Corticosteroid resistance in COPD (2)
29. PI3K-Akt pathway
30. Theophylline as HDAC activator
31. Theophylline restores steroid response
32. Reversal of smoke-induced inflammation
33. COPD patients: corticosteroids + theophylline
34. How does theophylline restore HDAC
35. PI3K-delta inhibition in vivo
36. PI3K-delta null mice
37. Nrf2 and antioxidant gene regulation
38. COPD comorbidities
39. Conclusions

Topics Covered

• Amplification of inflammation in COPD
• Inflammatory cells involved in COPD
• Role of macrophages in orchestrating inflammation
• Defective macrophage phagocytosis in COPD
• Mechanism of corticosteroid resistance in COPD
• Role of Nrf2

Links

Series:

• Advances in Chronic Obstructive Pulmonary Disease (COPD)

Categories:

• Biochemistry
• Cell Biology
• Clinical Practice
• Immunology

Therapeutic Areas:

• Immunology & Inflammation
• Respiratory Diseases

Talk Citation

Publication History

• Published on July 31, 2012

Financial Disclosures

• Peter Barnes receives research grants from AstraZeneca and Boehringer-Ingelheim and is an advisor and/or gives talks for AstraZeneca, Boehringer-Ingelheim, Covis, Novartis, Pieris and Teva.